Kensington Capital Acquisition Corp. IV (NYSE:KCAC) announced in an 8-K this morning that its shareholders have approved its combination with battery-maker Amprius with better-than-average redemptions.
At a special meeting September 13, Kensington IV shareholders voted to approve the deal with about 71.8% redeeming shares in connection with the vote. This is significantly below the 2022 average of about 85.5% shares redeemed for completed SPACs in 2022.
The deal originally had a minimum cash closing condition of $200 million, but this has been waived by Amprius. The redemptions leave an estimated $65.9 million in Kensington IV’s trust and this has been supplemented with a number of PIPE contributions adding up to $20.5 million.
Additionally, Kensington IV said in the filing that it expects to close the combination today and Amprius’ shares and warrants are expected to trade on the NYSE under the symbols “AMPX” and “AMPX.W”, respectively, on September 15.
The parties announced the $939 million deal on May 12. Amprius, the Freemont, California-based silicon nanowire battery company manufacturers high-energy and high-power lithium-ion batteries.
Last month, Amprius announced it had signed an agreement with Centrotherm to help it build out the equipment necessary for mass production of its silicon anode battery sells.
ADVISORS
- Hughes Hubbard & Reed LLP is serving as legal advisor and Marcum is serving as auditor to Kensington.
- Oppenheimer & Co. Inc. is serving as financial advisor, Wilson Sonsini Goodrich & Rosati is serving as legal advisor, and SingerLewak is serving as auditor to Amprius.
Perimeter Acquisition Corp. I (NASDAQ:PMTRU) announced the pricing of its upsized $210 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “PMTRU”, Tuesday, May 13, 2025. The new SPAC aims to combine with a target company with that can contribute to the re-industrialization of the United States economy,...
Horizon Space II (NASDAQ:HSPT) has signed a definitive agreement to combine with clinical stage biotech firm SL Bio Ltd. for $5.57 billion in equity consideration. Taipei, Taiwan-based SL Bio is developing drug candidates to treat several cancer types while also selling over-the-counter beauty products derived from natural extracts. The combined company is expected to trade...
At the SPAC of Dawn This is set to be a slower week for votes with just two SPACs seeking an extension and none yet scheduling a meeting for approving a business combination. Integrated Rail & Resources (OTC:IRRX) primed the pump somewhat for investors ahead of its Tuesday special meeting by announcing it has entered...
Terms Tracker for the Week Ending May 9, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. After the sprint that was last week, with nine IPOs and six new SPAC filings, this week took a breather. Only two SPACs priced, there...
Lake Superior (NASDAQ:LKSPU) has filed for a $100 million SPAC as its CEO attempts to go three-for-three with SPACs that led to completed deals. This new vehicle has one right to a 1/6 share in each unit and some common features of a SPAC underwritten by Cohen & Company in this current climate. Although the...